Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
Total revenue	$ 153,731	$ 67,772	$ 61,880
Vaxcyte Agreements
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
Total revenue	101,302	3,828	3,041
Vaxcyte Agreements | Upfront Payment
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
Total revenue	97,500
Vaxcyte Agreements | Research and Development Services
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
Total revenue	2,435	2,356	1,131
Vaxcyte Agreements | Materials Supply
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
Total revenue	1,367	1,472	1,910
Collaboration and License Agreements and Supply Agreements
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
Total revenue	153,731	67,772	61,880
Collaboration and License Agreements and Supply Agreements | Bristol-Myers Squibb Company ("BMS")
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
Total revenue	5,590	9,752	11,483
Collaboration and License Agreements and Supply Agreements | Merck Sharp & Dohme Corporation ("Merck")
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
Total revenue	5,869	11,600	42,780
Collaboration and License Agreements and Supply Agreements | Merck KGaA, Darmstadt, Germany (operating in the United States and Canada under the name ''EMD Serono'')
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
Total revenue	8	2,695	4,576
Collaboration and License Agreements and Supply Agreements | Astellas Pharma Inc. ("Astellas")
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
Total revenue	33,992	10,897
Collaboration and License Agreements and Supply Agreements | Tasly Biopharmaceuticals Co., Ltd. ("Tasly")
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
Total revenue	6,970	25,000
Collaboration and License Agreements and Supply Agreements | Vaxcyte, Inc.
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
Total revenue	101,302	3,828	3,041
Collaboration and License Agreements and Supply Agreements | BioNova Pharmaceuticals, Ltd. ("BioNova")
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
Total revenue		4,000
BMS Agreement and the 2018 BMS Master Services Agreement
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
Revenues	5,590	9,752	11,483
BMS Agreement and the 2018 BMS Master Services Agreement | Research and Development Services
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
Revenues	412	700	940
BMS Agreement and the 2018 BMS Master Services Agreement | Materials Supply
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
Revenues	5,178	9,052	10,543
2020 Merck Master Services Agreement
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
Total revenue	5,869	11,600	42,780
2020 Merck Master Services Agreement | Ongoing Performance Related to Unsatisfied Performance Obligations
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
Total revenue		862	35,098
2020 Merck Master Services Agreement | Contingent Payment
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
Total revenue		10,000
2020 Merck Master Services Agreement | Research and Development Services
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
Total revenue	245	577	2,666
2020 Merck Master Services Agreement | Financing Component on Unearned Revenue
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
Total revenue			610
2020 Merck Master Services Agreement | Materials Supply
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
Total revenue	5,624	161	4,406
2019 EMD Serono Supply Agreement
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
Total revenue	8	2,695	4,576
2019 EMD Serono Supply Agreement | Contingent Payment
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
Total revenue			2,000
2019 EMD Serono Supply Agreement | Research and Development Services
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
Total revenue	6	510	851
2019 EMD Serono Supply Agreement | Materials Supply
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
Total revenue	2	2,185	$ 1,725
Astellas License and Collaboration Agreement
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
Total revenue	33,992	10,897
Astellas License and Collaboration Agreement | Ongoing Performance Related to Unsatisfied Performance Obligations
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
Total revenue	17,015	3,940
Astellas License and Collaboration Agreement | Research and Development Services
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
Total revenue	6,584	1,878
Astellas License and Collaboration Agreement | Financing Component on Unearned Revenue
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
Total revenue	9,836	5,079
Astellas License and Collaboration Agreement | Materials Supply
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
Total revenue	557
Tasly License Agreement
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
Total revenue	6,970	25,000
Tasly License Agreement | Upfront Payment
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
Total revenue		$ 25,000
Tasly License Agreement | Contingent Payment
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
Total revenue	5,000
Tasly License Agreement | Research and Development Services
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
Total revenue	92
Tasly License Agreement | Materials Supply
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
Total revenue	$ 1,878